Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Solid consolidating 1.20's to 1.30's. going to fill gap eventually to mid $2's, then with any luck back over $5.
10,000.......hehehe, 1.7 after market, Tomorrow we can hit 2.5 space enough to allow everyone to get out with some profits
BXRX1.40 yes you were right, hope you have some!
Hope this uptrend continues.
I'm sitting on 36,000 shares of BXRX for a couple months,
averaged down recently, to about where we are now PPS.
Gap to $2.70 filling now , then to $6 later this quarter
Thank you! Perhaps hiring a sales force for their new FDA approved drug?
I’ll write to the company today, Im curious what kind of projects they have with the $10,000,000 usd of the offering.
time will dictated, rewards for patience investors.... buy - hold
End of year form 4's. Taking advantage.
(1) Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
(2) Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
https://ih.advfn.com/stock-market/NASDAQ/baudax-bio-BXRX/stock-news/83868235/statement-of-changes-in-beneficial-ownership-4
Some just don't understand this strategy and how common it is. Anyway, I'll be building a position here and looking forward to seeing this grow.
Me and you only ones rooting for this here, but they have ammunition if they unload skillfully.
Adding more tomorrow at $1.15
Well to me looks like the offering was completed! TIME TO MOVE UP!!$$
BXRX 1.26 sucked to .97 since you wrote that stupid comment but
today waking up a bit for no news mystery?
Appreciate your response and thoughts on this very much. I’ll keep researching this company. Take care
Superficially most compelling idea I had for years, but ya don't know what you don't know, and in truth not privy to financial challenges this company has to implement to boost their drug sales, and they have process to dilute investors eager to overlook these facts. That is this rapid decline from 3.36 some weeks ago to about 1 third of present value, on PR news of sales guidance must cause apprehension and unavoidable unknown risk chasing investors away.
Hi, curious if you believe this has an opportunity to flourish into a serious investment opportunity? TIA for any guidance
BXRX: 2.79 start, OCT 1 change in code , so price drop offers cushion for more opportunity if it drops further on who knows why it drpped on edge of getting first large sales?
A big run on no news
BXRX 3.62 something to those signals.
BXRX 3.36 nice "tell".
Annnnnnd back down AH to 4.36
Solid move
@Tickle
Give it a look.
Could run to $6 by end of next week
Congrats again on SEEL!
Cheers!
You've peaked my interest...
Cheers
YESSS ! Make em cover a lot higher. Has to break 10.50 as that when they started shorting. Right after FDA approval.
KILL THE BXRX SHORTS!
We are here to Kill the BXRX Shorts.
Read the details here:
https://seekingalpha.com/instablog/50299941-north-shore-research/5463523-new-kill-shorts-bxrx
BXRX Steady March Up. Doubled my position at 4.20 last week.
* * $BXRX Video Chart 05-15-2020 * *
Link to Video - click here to watch the technical chart video
Love it.
Loaded up under 3...
Easy money here - someone will be very happy to buy whatever you hold @ $10 in the not so distant future, as they were all but a few weeks ago!
I'll be buying any dips and holding through the rips until the mkt cap better reflects the staggering potential of Anjesco.
Article Describing their sales preparations, 3 weeks old but still relevant today:
Baudax Bio Inc. said Tuesday its first product, Anjeso, is now available for ordering and delivery to customers. However, because of the ongoing coronavirus pandemic, the Malvern company is relying on nontraditional methods to promote its new non-opioid pain medicine.
Gerri Henwood, CEO of Baudax Bio (NASDAQ: BXRX), told the Business Journal the company's original plan was to launch the product later this month, but the pandemic has caused delays in hiring a full sales team — and made it unfeasible to call on potential customers in their offices.
“These are challenging times for everyone involved in the delivery of health care in the United States, and the well-being of everyone involved remains our top priority," Henwood said.
Henwood said the company has maintained a small, core commercial team while Anjeso was under regulatory review. That 20-person team has been conducting "virtual outreach" to discuss the new medicine with customers — such as surgeons, anesthesiologists and hospital formulary committees — rather than scheduling face-to-face meetings.
"We knew there were people who had a familiarity with the product, and we wanted to make it available to them," she said. "We are diligently working to hire and train our field sales force and expect to execute the full Anjeso commercial launch by later in the second quarter."
B
The Food and Drug Administration approved the non-steroidal, anti-inflammatory drug in February as a treatment for moderate-to-severe pain.
Anjeso, which is delivered intravenously once a day, is designed to be administered to patients in the hospital or in other acute care settings.
Baudax raised $25 million in a public stock offering last month to support the launch of the product.
John Harlow, Baudax's chief commercial officer, said the company was able to conduct some job interviews prior to the work-from-home orders that accompanied the coronavirus outbreak. He said the company expects to bring in about 50 sales representatives in mid-May.
Baudax plans to use virtual training and virtual launch meetings to get the staff ready.
The virtual outreach the company has been conducting with customers, Harlow said, has involved proactively emailing and setting up video calls. "We've been having one-on-one and a-few-on-one conversations with potential customers," he said.
Harlow said they have also implemented a "full-scale" online campaign that uses the company's website to provide information about the product, how to use it and how to order it, along with reimbursement information and "follow-up" tools.
In addition, Harlow said the company began an advertising campaign featuring online banner ads and journal ads for Anjeso.
Baudax Bio was created late last year when Recro Pharma (NASDAQ: REPH), also based in Malvern, split into two companies. The move allowed Recro to focus on its contract manufacturing and business, while Baudax focuses on product development. Henwood is the CEO of both publicly traded companies.
https://www.bizjournals.com/philadelphia/news/2020/04/07/malvern-pharma-firm-turns-to-virtual-outreach-for.html
Holding from 2.70
Baudax Bio, Inc. (BXRX)
Specializing in the development of products for patients in acute care settings, Baudax Bio is committed to providing clinically meaningful therapeutic options. Shares are up 25% in the last month, and some market watchers believe that there’s still plenty of room for BXRX to keep on surging.
This appears to be the stance taken by Boyd. Armistice initiated a new position, pulling the trigger on 899,576 shares. Along with the purchase came a 4.99% stake in BXRX.
Weighing in on the healthcare name for Janney Montgomery, analyst Esther Hong has also been singing its praises. Her bullish thesis is in part driven by the company’s plans for its IV meloxicam (Anjeso) product’s U.S. launch. The therapy, which was approved back in February for the treatment of moderate-to-severe post-op pain, will be launched in June, with the company placing a significant focus on hiring and training a sales staff in preparation for the full commercial launch.
Hong tells investors that once COVID-19 restrictions are eased, she predicts a spike in elective surgeries. As a result, her call for de minimis U.S. Anjeso sales of $3.1 million for the first six months after launch remains unaltered.
Hong added, “Once the recommendation against non-emergency procedures is lifted, we believe Baudax will move full speed forward with its plans to target ambulatory surgical centers (ASCs) that perform the following core target procedures: orthopedic (hip/knee, spine, other), general surgery and colorectal. This translates to approximately 550 ASC accounts that perform approximately 1 million of these procedures per year.” As BXRX has also identified 1,450 inpatient and outpatient hospitals that make up 80% of the targeted market, the deal is sealed for Hong.
As a result, Hong rates BXRX shares a Buy along with a $10 price target, which implies 190% upside potential. (To watch Hong’s track record, click here)
Other analysts are on the same page. Based on 100% Street support, BXRX earns a Strong Buy consensus rating. In addition, the $13.33 average price target is more aggressive than Hong’s and suggests 291% upside potential. (See Baudax stock analysis on TipRanks)
https://finance.yahoo.com/news/healthcare-investor-steven-boyd-gobbling-140257476.html
Some nice power point slides there. I always like to see no debt....the $17 mil cash doesn't hurt. Should break through $3 soon enough!
Some interesting info on Baudax Bio site published today :
https://www.baudaxbio.com/news-and-investors/presentations
Great data published today. Must-read. Could be a ten bagger.
https://finance.yahoo.com/news/baudax-bio-announces-presentation-phase-110010904.html
In cases like these, being early is much better than being late. This company didn't exist before Nov 2019 and the spinoff. That creates a big opportunity for those lucky enough to have found it.
Don't worry though. Once sales news will start popping up, the crowd will notice. Hopefully we'll be trading back up at $8 by then. IMHO.
this is a winner while everyone seems only worried about covid this sleeper is coming strong on very good volume. I can not be the only one seeing this
For comparison: $PCRX who's bread-winner is EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements, has revenues of about $400M. It trades at 4 times revenue.
If as analysts predicts, $BXRX reaches peak revenue of $350M, if you apply an even lower multiple, say 2.5, you'd get to a $875M market cap.
If fully diluted we end up with 25M shares --> you'd get at a share price of: 35$ !!!!!!
If Peak sales are overestimated and we just get half of it, PPS should still be, if you follow $PCRX metric at: $17!!!!
THAT IS A 630% GAIN FROM TODAY'S PRICE ($2.7)!!!!!!!!!!!!!!!
"Risk Assessment
Baudax is expecting ANJESO to receive a 3-year Regulatory Exclusivity as it enjoys multiple patents covering its formulation, product by process additional formulation patents and 3 additional patents regarding the reduction of flake-like aggregates.
The Company is targeting a potential $6 billion market for IV pain management and intends to start with over 300 fast start accounts that have been vetted by their field team and prioritized in anticipation of the launch. Baudax has set its sights on more than 1450 hospital accounts and 550 ASC’s with an initial focus on 800-1000 accounts on launch. In addition, the Company intends to apply for a C-Code and J-Code in March 2020 and April 2020 respectively.
A good sales team is prerequisite for the success of any new drug in the market and the Baudax is no exception. The Company has plans to set a marketing team in place with John Harlow, the Company’s Chief Commercial Officer revealing that Baudax will bring in 50 sales representatives, 5 regional business directors and five account managers on board in the event of IV meloxicam being approved by the FDA. Efforts are on to make the product available in the market in seven to eight weeks.
The Company is helmed by a management team with extensive experience in commercial launch, product development and regulatory framework. This will hold the Company in good stead, as demonstrated by its handling of two rejections from the FDA for ANJESO.
Baudax had cash and cash equivalents worth $17.7 million as of December 31, 2019 and no debt. The Company believes that it would be enough to fund its clinical development and commercial launch activities associated with ANJESO.
Opioid Addiction is a growing epidemic which has reached an endemic proportion in the U.S. Prescription drug overdose is one of the leading causes of preventable deaths in the U.S, prompting the government to declare a public health emergency in 2017. There is stringent regulatory control and negative perception towards opioid based drugs, which makes it an extremely challenging environment for drug development and commercialization for any company."
https://www.aviseanalytics.com/baudax-bio-scores-a-big-win-with-the-fda-approval-of-anjeso/
This is a multi-bagger at these levels. They may need more money for commercialization and thus dilute a bit more though I think with the $50M and the $20M loan they are talking about, they should be fine.
They are a buy-out target for sure. If peak sales are really in the $300M ballpark. This could be a Billion dollar company in the next 2 to 3 years: Yes a 25 bagger. You read that correctly.
For the moment they are below the radar of most as they just spun off from REPH.
This shouldn't last.
Fasten your seatbelts. They plan to launch their new FDA approved drug by end of Q2... in max 10 weeks.
* * $BXRX Video Chart 03-24-2020 * *
Link to Video - click here to watch the technical chart video
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
404
|
Created
|
11/26/19
|
Type
|
Free
|
Moderators |
March 26, 2020 | 17.57M |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.28 | 6,500 | 14,820 | 6,500 | Mar 30 08:00 PM |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.44 | 25,000 | 61,000 | 52,782 | Mar 30 08:00 PM |
Weisman Wayne | Director | Mar 26 | Buy | 2.29 | 10,000 | 22,900 | 40,582 | Mar 27 03:53 PM |
ALTOMARI ALFRED | Director | Mar 26 | Buy | 2.34 | 5,000 | 11,700 | 33,382 | Mar 27 03:51 PM |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |